Last updated: May 24, 2026
CLOBEX (clobetasol propionate) Suppliers: API, Finished-Dose, and Contract Manufacturing Landscape
Clobex is a branded topical clobetasol propionate product. Supplier coverage for “Clobex” depends on whether the inquiry targets (1) clobetasol propionate API makers, (2) finished-dose drug product manufacturing, or (3) secondary distributors and “authorized generics” under FDA arrangements.
No source-ready supplier list can be produced for “CLOBEX suppliers” from the information provided in this request alone. Patent and FDA-specific supplier identification requires tied records (e.g., FDA Orange Book/manufacturer of record for NDC strengths, labeling/CMC sites, or corporate supply disclosures). Without those tied records, any supplier list would risk being incomplete or inaccurate.
What suppliers make clobetasol propionate (Clobex API) for topical products?
Featured snippet answer: API supplier lists for clobetasol propionate are not uniquely mapped to “Clobex” without the specific NDC and manufacturing-of-record for the finished product.
How to identify API suppliers vs. finished-dose manufacturers
- API suppliers: Companies filing DMFs and/or supplying clobetasol propionate to multiple topical products across brands and generics.
- Finished-dose suppliers: The labeled manufacturer(s) and/or applicant on the FDA label for the specific Clobex NDC strength and dosage form.
- Distribution entities: Wholesale or logistics partners that do not manufacture.
Typical supplier sources used in due diligence
- FDA Orange Book entries for the specific NDC strength/dosage form (to identify applicant/labeler and listing).
- FDA Drug Approvals and Labeling records for the branded product.
- DMF listings tied to the API for clobetasol propionate.
- Corporate CMC statements for the labeled manufacturer of Clobex.
Which companies manufacture Clobex finished product by NDC strength and dosage form?
Featured snippet answer: Clobex manufacturing-of-record must be mapped to the exact NDC.
Why NDC-specific mapping matters
Clobex exists as a topical solution (clobetasol propionate). Manufacturing and packaging sites can vary by:
- strength
- packaging configuration
- label revision cycles
- contract manufacturing changes over time
What is the Orange Book status of Clobex and what does it reveal about suppliers?
Featured snippet answer: Orange Book records can identify the applicant/holder and sometimes the manufacturer of record, but they must be pulled for the specific NDC.
What to extract from Orange Book for supplier work
- Proprietary name (Clobex)
- Applicant/holder
- Dosage form and strength
- Patent(s) listed (useful for understanding market competition and whether generics are approved)
- Exclusivity and patent expiration drivers (useful for supply stability analysis)
Who holds the NDA/labeler for Clobex and how does that map to contract manufacturing?
Featured snippet answer: The NDA holder and labeler are not the same thing as the contract manufacturing sites.
Manufacturing mapping method used in licensing and procurement
- Identify the NDA holder/labeler
- Cross-check the FDA label “Manufactured for” or “Distributed by” statements
- Verify CMC sites in regulatory filings and inspections (where available)
- Compare across revisions to detect supply chain changes
How many clobetasol propionate suppliers exist globally for topical formulations?
Featured snippet answer: The total number of clobetasol propionate API suppliers is typically larger than the number of Clobex finished-dose manufacturers, but the exact count depends on scope and data source.
Supplier landscape segmentation
- API-only suppliers
- Finished-dose formulators
- Regional contract manufacturers serving US and non-US markets
- License-and-manufacture arrangements where one site produces for multiple brands
What generic and authorized generic risks affect Clobex supply and sourcing?
Featured snippet answer: Supplier risk is tied to patent and exclusivity status only when multiple approved/launching entrants increase procurement competition.
How exclusivity and patent posture changes supplier dynamics
- Earlier entry of generics can increase demand for API and drug product capacity
- Patent litigation outcomes can freeze or restart sourcing contracts
- Shortages can shift manufacturing to alternate sites
What contract manufacturing barriers exist for topical clobetasol propionate solutions?
Featured snippet answer: CMC and potency control are the key barriers, but exact risk depends on the formulation and strength.
Typical manufacturing/IP constraints
- controlled mixing and potency verification for high-potency corticosteroids
- container closure and light/heat stability qualification for solutions
- packaging compatibility with the solution vehicle
- validated analytical methods and stability protocols
- regulatory inspection history of manufacturing lines
Which distributors supply Clobex in the US and who are the wholesale intermediaries?
Featured snippet answer: Wholesale distributors vary by region and contract year; they are not intrinsic to “Clobex” without NDC-level sourcing data.
Procurement-specific view
- Pharmacy supply chain uses multiple intermediaries
- Some inventories come via direct buy or through group purchasing organizations
- Hospitals and IDNs often use contracted GPO channels
Key Takeaways
- A definitive “Clobex suppliers” list requires NDC-specific FDA and label records tied to the finished product.
- “Suppliers” can mean API manufacturers or finished-dose manufacturers; they are different groups.
- Orange Book and FDA labeling are the core sources used to identify the manufacturer-of-record/labeler, but they must be pulled for the exact Clobex NDC/strength.
FAQs
- What is the difference between clobetasol propionate API suppliers and Clobex finished-dose manufacturers?
- How does NDC-level labeling determine who manufactures Clobex solution?
- What does Orange Book applicant information reveal about Clobex sourcing and supply stability?
- How do patent and litigation events influence availability and procurement of high-potency topical corticosteroids?
- What CMC constraints typically affect contract manufacturing of clobetasol propionate topical solutions?
References
- U.S. Food and Drug Administration (FDA). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Database).
- U.S. Food and Drug Administration (FDA). Drugs@FDA: FDA-Approved Drugs. (Database).
